SOGP Recommendation for the Diagnosis and Management of Iron Deficiency Anaemia in Pregnancy and Postpartum

Authors Contribution

Prof. Muhammad Al Fareed Zafar, Prof. Arif Tajammul, Prof. Sonia Naqvi, Prof. Huma Quddusi, Prof. Sadaqat Jabeen, Prof. Yousaf Latif Khan

Scope and Purpose

These guidelines were formulated under the chair of Prof. Muhammad Al Fareed Zafar with a team of experts from across Pakistan. Prof. Sonia Naqvi oversaw and coordinated for the preparation of this document. The technical contributions came from the team members comprising: Prof. Muhammad Al Fareed Zafar, Prof. Sonia Naqvi, Prof. Arif Tajammul, Prof. Huma Quddusi, Prof. Sadaqat Jabeen, and Prof. Yousaf Latif Khan. We would like to express our gratitude to the members of this committee for their technical support throughout the process.

We also gratefully acknowledge the technical inputs of Professor Olus Api, MD, Yeditepe University Hospital, Clinic of Gynecology and Obstetrics, İstanbul, Turkey.
Introduction

Global Burden of Disease

The prevalence data for anaemia is an important indicator in public health as it is related to morbidity and mortality in the most vulnerable population groups including pregnant women and children under five.\(^1\) Three groups show the highest prevalence for anaemia: pregnant women (42%), women of reproductive age (30%) and children under 5 years of age (47%) with iron deficiency accounting for almost 50% of cases as the most common cause.\(^2\) Anaemia during pregnancy is a public health problem especially in developing nations and is associated with adverse outcomes in pregnancy.\(^3\) The World Health Organization (WHO) has defined the cut off value for anaemia in pregnancy as the haemoglobin (Hb) concentration of less than 11 g/dl during the first and third trimester of gestation is lower than 11g/dl whereas in the second trimester of pregnancy, the haemoglobin concentration further decreases by approximately 0.5g/dL.\(^4\),\(^5\)

The global statistics for mean haemoglobin improved between 1995 and 2011 in non-pregnant women from 12.5 g/dL to 12.6 g/dL, in pregnant women from 11.2 g/dL to 11.4 g/dL, and in children from 10.9 g/d to 11.1 g/dL and concurrently the prevalence of anaemia fell from 33% to 29% in non-pregnant women, from 43% to 38% in pregnant women, and from 47% to 43% in children.\(^6\) The WHO country estimates for Pakistan (2011) report noted anaemia as a severe public health problem: the mean blood Hb levels for pregnant women aged 15–49 years were 10.9 g/dL, percentage of pregnant women with blood Hb level (<11.0 g/dL) were 50%, and percentage of pregnant women with blood Hb levels (<7.0 g/dL) were 2.1%.\(^7\)

Globally, iron deficiency anaemia (IDA) in women of reproductive age, affects 17% of women including 15% (248 million) of non-pregnant and 19% (16.2 million) of pregnant women.\(^8\),\(^9\) It affects nearly 700 to 800 million people worldwide. In the developing countries the rate of anaemia in pregnant women stands at 56% and almost 65% of pregnant women in South Asia suffer from IDA. Notably 88% women in the Indian subcontinent area develop IDA during pregnancy.\(^10\),\(^11\)
The reported prevalence of IDA in Pakistani women is between 30-60%.\textsuperscript{12} Prevalence of anaemia among women of reproductive age (\% of women ages 15-49) in Pakistan was 52\% as of 2016. Its highest value over the past 26 years was 53.60\% in 1990, while its lowest value was 48.80\% in 2001.\textsuperscript{13} The National nutrition survey 2011 of Pakistan reported that 51\% of pregnant mothers suffered from IDA.\textsuperscript{14} Numerous small studies showed a great variation in the extent of prevalence of IDA in Pakistan e.g. 48.2\% of the pregnant women were shown to be anemic while 90.5\% of the total tested pregnant women suffered from IDA.\textsuperscript{15}

**Etiology**

Anaemia among pregnant women in developing counties presents a multifactorial etiology.\textsuperscript{16} Increased iron needs may be due to a variety of reasons including: the increasing needs of the body as part of development, blood loss, worm infestation, pregnancy, infections, poor absorption of iron due to diets high in phytates, inflammatory bowel disease or blood donation. Furthermore, there is an additional higher risk of developing anaemia in women who have gynecological diseases or have heavy blood loss during menstruation. Genetic disorders like thalassemia and sickle cell disease are also associated with and aggravated by the presence of anaemia.\textsuperscript{17} Bone marrow diseases that cause suppression of red cells synthesis, chronic renal failure, rheumatoid arthritis and tuberculosis are some additional causes that lead to anaemia.\textsuperscript{18} The causes of IDA in Pakistan are numerous. A few amongst the many include: early marriage and multiple childbirths, malnutrition and poor diet, lack of awareness, illiteracy, improper supplementation of iron in pregnancy (late registration and poor follow-up), untreated systemic disease, menstrual disorders, poor socio-economic conditions, high consumption of cereals, legumes, and plant-based diets. However, data are scant to precisely gauge the level of IDA prevalence relevant to these determinants in Pakistan.\textsuperscript{10} Numerous studies from Pakistan report that amongst the many risk factors associated with IDA the main ones are; household food insecurity, nutritional deprivation, low meat intake, absence of eggs in diet or consumption less than twice a week during pregnancy, drinking more than three cups of tea per day before pregnancy, consumption of clay or dirt during pregnancy, pica, worm infestation, pan & manpuri, acute blood loss during pregnancy because of antepartum haemorrhage or haemorrhoids, education, absence of iron folic acid supplementation during the last pregnancy, multiparity of four or more pregnancies, birth spacing of less than 24 months, low monthly income and presence of clinical anaemia.\textsuperscript{12,15,19,20}
Sign and Symptoms

As mild anaemia may be asymptomatic it may get diagnosed during screening on routine prenatal checkup for haemoglobin levels. As anaemia advances to moderate and severe literature review shows that it can present with various common and typical signs and symptoms amongst many such as: pale looking patient with dizziness, fatigue, lethargy and generalized weakness, irritability, cold intolerance, poor concentration, shortness of breath, frequent minor infections, sore throats, headache (frontal), pica (unusual craving for non-food items such as ice and dirt), decreased appetite and dysphagia (owing to postericoid oesophageal web), GI discomfort and weight loss, ringing in the ears. Other clinical signs of anaemia include pallor, blue sclera, pale conjunctiva, skin and nail changes (brittle nails, koilonychia), leg oedema, gum and tongue changes (smooth tongue/ glossitis and stomatitis), tachycardia and functional heart murmur.\textsuperscript{21,22,23,24,25}

Consequences

In Asia, anaemia (irrespective of the severity) is the second leading cause of maternal death accounting for 12.8\% independent of deaths due to postpartum haemorrhage.\textsuperscript{26} Similarly, other studies quote that about 20\% of maternal deaths are caused by anaemia and hence anaemia is an additional risk factor in contributing 50\% to all maternal deaths. Anaemic pregnant women are prone to severe morbidity and mortality as well as poor fetal outcomes in developing countries. As stated by the State of the World Population 2017 maternal mortality ratio of Pakistan was 178 deaths per 100,000 live births.\textsuperscript{11,27} Various surveys have shown different rates but they are all high and are a need for concern. According to Pakistan demographic and health survey 2012-2013, in rural areas, 26 percent of women made at least 4 antenatal care (ANC) visits compared to 62 percent in urban areas. Coverage of the skilled attendant at birth is 44 percent in rural areas, compared to 71 percent in urban areas.\textsuperscript{28}

Iron deficiency contributes to maternal morbidity through effects on immune function with increased susceptibility and severity of infections, poor work capacity, low performance and postpartum cognition and emotions. Maternal iron depletion also leads to significant neonatal morbidity in the form of increased risk of iron deficiency in the first 3 months of life, impaired psychomotor and/or mental development and can also negatively contribute to the infants social
emotional behaviour. There is also evidence of the association between maternal iron deficiency and preterm delivery, low birth weight, possibly placental abruption and increased peripartum blood loss.\textsuperscript{21} Several large epidemiological studies have demonstrated that maternal anaemia is associated with premature delivery, low birth weight, and increased perinatal infant mortality.\textsuperscript{29}

**Guideline Development Methodology**

A group of experts developed the present evidence based recommendations. The steps in this process included: identification of priority questions and outcomes, retrieval and assessment of the evidence, formulation of the recommendations and also considered is its dissemination and implementation and later on impact evaluation and updating of the guideline as deemed necessary and appropriate.\textsuperscript{30}

This consensus group consisted of content experts, methodologists, and representatives of potential stakeholders and beneficiaries. This expert group participated in a technical consultation, concerning these consensus recommendations, held on 05–07 November 2018 in Istanbul, Turkey with inputs from international experts. Additional, support was also taken from WHO materials as referenced at the end of this document.

**Diagnosis**

**First Line Investigations:**

1. **Haemoglobin**

Haemoglobin is the first screening test. The cut off limit has been identified by WHO and RCOG as 11g/dL.\textsuperscript{31,32} But CDC (Centre for Disease Control) has established the value trimester wise as well as in the postnatal period i.e., 11g/dL in first and third trimester, 10.5 g/dL in second trimester and 10 g/dL in postnatal period.\textsuperscript{33} Severity of anaemia have also been described by WHO as mild 10-10.9 g/dL, moderate 7-9.9 g/dL and severe < 7g/dL.\textsuperscript{31} Haematocrit or packed cell volume have no advantage over haemoglobin measurement.\textsuperscript{31,34}

2. **Full blood count, red cell indices and RBC’s morphology**

Full blood count, red cell indices and RBC’s morphology should be the 1\textsuperscript{st} line of investigation.\textsuperscript{35} These should be advised at booking and at 28 weeks.\textsuperscript{34,36} Red Cell Indices can provide sensitive
indication of iron deficiency anaemia in the absence of chronic disease or haemoglobinopathy. Decreased RBC’s count, WBC’s count and platelet count will direct to the diagnosis of aplastic anaemia and confirmation of diagnosis will be done by bone marrow study.

RBC’s morphology i.e. MCV, MCH, MCHC helps in the diagnosis of different types of anaemia and will help in the selection of next line of investigations. Microcytic, hypochromic i.e. decreased MCV, MCH and MCHC (MCV < 76fl, MCH < 27 pg) shows iron deficiency anaemia, while decreased MCH, MCV and normal/decreased MCHC will identify haemoglobinopathies, whereas normochromic normocytic (Normal MCV, MCH and MCHC) will point towards acute blood loss or chronic illness like acute chronic inflammation, malignancy, liver disease and renal disease. Other tests either assess iron stores or the adequacy of iron supply to the tissue.  

3. Serum Ferritin

Serum Ferritin is the most specific biochemical test for total body iron stores in the absence of inflammatory changes. It is not effected by recent iron ingestion. Ferritin levels below 30µg/l should prompt treatment and levels below 15µg/l are diagnostic of established iron deficiency. Commonly reported threshold of 15 µg/l is specific but can be expected to miss as many as half the cases of iron deficiency anaemia. A serum ferritin concentration < 30 µg/l together with a Hb concentration < 11 g/dL during the 1st trimester, < 10.5 g/dL during the 2nd trimester, and < 11 g/dL during the 3rd trimester are diagnostic for iron deficiency anaemia during pregnancy. Serum Ferritin may give falsely high values, when there is coexisting infection or inflammation and being an acute phase reactant it may be normal or even elevated in inflammatory conditions despite the presence of anaemia. Therefore in such conditions serum Ferritin < 100 µg/l would be suggestive of iron deficiency.

Second Line Investigations:

1. Other indicators of iron deficiency anaemia

Other indicators include low transferrin saturation, low serum iron level, raised total iron binding capacity, raised red cells zinc protoporphyrin and increased serum transferrin receptors (sTfR). Percentage saturation of transferrin iron and free erythrocytic protoporphyrin values do not become abnormal until tissue stores are depleted of iron. Transferrin saturation (TSAT) can be considered as an alternate or complementary to serum Ferritin. These tests can be used to
determine iron status but also present challenges in interpretation. Serum transferrin receptor is not widely used in clinical practice in many countries.

2. Functional iron deficiency anaemia

Functional iron deficiency anaemia occurs when there is inadequate iron supply to bone marrow in the presence of storage iron in the cells such as in chronic diseases; CRP (C Reactive Protein) helps in differentiating between iron deficiency anaemia and other conditions such as inflammatory bowel disease, kidney disease, aplastic anaemia, autoimmune disease, hepatitis, HIV, radiation and chemotherapy. Percentage of hypochromic red cells (% HRC) is the best established variable and reticulocyte count is the next most established option. Serum Ferritin > 100 µg/l, CRP > 30, Iron < 7µmol/L, iron saturation < 20, TIBC < 45 µmol/L, are suggestive of chronic diseases.
Algorithms for the diagnosis of iron deficiency anaemia during pregnancy

- **ANAEMIA**
  - **Nutritional Anaemia**
    - Iron Deficiency
      - Serum Ferritin
      - HB Electrophoresis
      - TIBC
      - S. Iron
    - Folate Deficiency
      - Serum Folate
      - Red Cell Folate Level
  - **Haemoglobinopathies**
    - Vitamin B-12 Deficiency
      - S. Vitamin B-12 Level
    - Thalassemia Trait
      - Red Cell Folate Level
    - Hemoglobinopathies
      - Nutritional Anaemia
      - Hemoglobinopathies
  - **Aplastic Anaemia**
    - Bone Marrow
  - **Acute Blood Loss**
    - Haemoglobin
      - MCV
      - MCH
      - MCHC
      - Serum Ferritin

**Laboratory investigations**

- **Iron Deficiency**
  - Haemoglobin
  - MCV
  - MCH
  - MCHC
  - Serum Ferritin
- **Folate Deficiency**
  - Serum Folate
  - Red Cell Folate Level
- **Vitamin B-12 Deficiency**
  - S. Vitamin B-12 Level
- **Thalassemia Trait**
  - Haemoglobin
  - MCV
  - MCH
  - MCHC
  - Serum Ferritin
  - Hb Electrophoresis
- **Aplastic Anaemia**
  - Bone Marrow
- **Acute Blood Loss**
  - Haemoglobin
    - MCV
    - MCH
    - MCHC
    - Serum Ferritin
Haemoglobin
< 11 g/dL  1st and 3rd Trimester
< 10.5 g/dL 2nd Trimester
< 10 g/dL Postnatal

Complete Blood Count
RBC Morphology
Red Cell Indices

↓ RBC
↓ WBC
↓ Platelet

Pancytopenia

Bone Marrow Study

↓ RBC’s
↓ MCV
↓ MCH
↓/N MCHC

Iron Deficiency
Thalassaemia Trait
Chronic Disease
Sidroblastic Anaemia

< 30 µg/L
Iron Deficiency Anaemia

30–100 µg/L
Iron Studies

MCV N
MCH N
MCHC N

S. Ferritin Level

> 100 µg/L

↑ S. Ferritin Level

Haemoglobinopathies
Thalassaemia Trait
Sidroblastic Anaemia

Hb Electrophoresis

Normal/Abnormal Thalassaemia Trait

Functional Iron Deficiency

CPR >30
Iron < 7 umol/L
Iron Saturation < 20%
TIBC < 45 umol/L

Iron replete

S. Folate Level
S. Vitamin B-12 Level

MCV ↑ (> 96fl)

Non Haematological Causes
Acute / chronic illness
Inflammation
Malignancies
Liver disease
Renal disease

Bone Marrow Study

Iron replete

Confirm by Bone Marrow
Recommendations

Screen for Anaemia at the First Prenatal Visit
- All pregnant women should be screened for iron deficiency anaemia.
- The defined values consistent with anaemia in pregnancy are haemoglobin levels less than 11 g/dL (110 g/L) in the first or third trimester, or less than 10.5 g/dL (105 g/L) in the second trimester. A trial of oral iron therapy can be both diagnostic and therapeutic. If haemoglobinopathies status is unknown, then it is reasonable to start oral iron therapy whilst screening is carried out. A trial of oral iron should demonstrate a rise in Hb within 2 to 3 weeks and this will confirm the diagnosis of iron deficiency. If there is no rise, further tests must be carried out. In patients with a known haemoglobinopathies serum ferritin should be checked first. If the first prenatal visit occurs in the first trimester, draw blood and determine haemoglobin and ferritin concentrations.

Screen for Anaemia at the Second Trimester Visit
- At a scheduled second-trimester visit, or if the first prenatal visit occurs in the second trimester, obtain a blood specimen and determine the haemoglobin and serum ferritin concentrations.

Screen for Anaemia at the Third Trimester Visit
- At a scheduled third-trimester visit, or if the first prenatal visit occurs in the third trimester, obtain a blood specimen and determine the haemoglobin concentration.

Screen High Risk Women for Anaemia at the 4 - 6 Week Postpartum Visit
- Screen women at high risk for iron deficiency anaemia at the 4 - 6 week postpartum visit (risk factors include anaemia continued through the third trimester, excessive blood loss during delivery, or multiple births). Obtain a blood specimen and determine the haemoglobin concentration.
- Postpartum anaemia is defined as Hb < 10 g/dL
- Measurement of the serum ferritin level is the most accurate test to diagnose iron deficiency anaemia
- Serum ferritin level always correlates with CBC especially with Hb levels.
- Ferritin and Hb level should be used as diagnostics marker for ID & IDA in prepartum and postpartum period.

Treatment

The public sector in Pakistan offers a wide network of health care facilities extending from the primary to the tertiary care level from the platforms of the basic health units (BHU), rural health centers (RHC), tehsil/district headquarters hospitals (THQ/DHQ) and various civil hospitals. The private hospitals, on the other hand provide greater access through an out-of-pocket model but
offer mostly tertiary care. The diagnostic services vary from facility to facility in the public sector both in terms of standards and variety of tests. The private sector, however, provides a greater network of collection services and standardized labs for improved wider spectrum of diagnostics. Therefore, as diagnostics and consequent treatment protocols may not be harmonious across the country, patients do not have access to standard antenatal, intrapartum and postpartum care resulting in high maternal mortality. This number varies according to the particular survey and is stated as 260 / 100,000 live births by the recent Pakistan Demographic and Health Survey (PDHS 2017/18).

IDA is the most prevalent nutritional deficiency in Pakistan. Amongst the many factors, food insecurity, poor nutrition, repeated pregnancies and unhealthy dietary habits have been associated with its onset amongst the vulnerable populations as stated earlier. Pregnant women are at special risk of iron deficiency anaemia due to increased requirements which are difficult to cover with our current diet alone. Most women in our country embark on pregnancy with depleted iron stores.

A haemoglobin level of less than 11 g/dL in the antenatal period should be suspected as iron deficiency anaemia (IDA) unless proven otherwise (such as Thalassaemia). The most sensitive and specific test to diagnose iron deficiency is serum ferritin level with a cut off value of less than 30 µg/L, indicating poor iron stores. Daily iron and folic acid supplementation is recommended as part of the antenatal care to reduce the risk of maternal anaemia and iron deficiency leading to increased maternal, fetal and new born complications.

Strategies to combat IDA include counselling services, food fortification, dietary modification, supplementation, and deworming. It is imperative to provide dietary advice to pregnant women at the time of booking, especially those belonging to the poor socio-economic strata.

Oral iron supplementation is usually the first choice for the treatment of iron deficiency anaemia (IDA) because of its effectiveness and low cost. But unfortunately in many iron deficient conditions, oral iron is a less than the ideal treatment mainly because of adverse events related to the gastrointestinal tract as well as the long course required to treat anaemia and replenish body iron stores.

Because of the high rate of gastrointestinal AE’s (35% to 59%) with ferrous sulfate, new compounds containing either the ferric or ferrous salt forms have been developed as different preparations (amino acid chelates, carbonyl iron, iron III polymaltose complex [IPC], extended
release products) and are approved for clinical use. Among these, IPC is the most studied and used for IDA patients based on its better tolerability leading to higher compliance rates and improved effectiveness.\textsuperscript{48}

Treatment with IV iron is clearly superior to oral iron and presents several advantages such as quicker and higher increase in Hb levels and replenishment of body iron stores. The ferric hydroxide preparation was the first iron compound for parenteral use but had severe toxic reactions. This was followed by the high molecular weight iron dextran (HMW-ID) which was associated with an elevated risk of anaphylactic reactions and low molecular weight iron dextran (LMW-ID) requiring a test dose and had black box warnings. Ferric gluconate (FG) and iron sucrose (IS) offered safer alternatives to HMW/LMW-ID. By far the greatest experience in published literature is with IS. The more recent products ferric carboxymaltose (FCM), iron isomaltoside, and ferumoxytol offer better safety profiles than the more traditional IV preparations, particularly because these products may be given more rapidly and in larger doses than their predecessors with the possibility of complete replacement of iron in 15-60 minutes. A warning has been issued for ferumoxytol about potentially life threatening events. FCM has an efficiency ratio over 10 times better than IS and does not have the requirement of a test dose.\textsuperscript{48}

1. Prenatal treatment:

1st Trimester

Most women in Pakistan are not able to see the health care provider in the 1\textsuperscript{st} trimester of their pregnancy, and this problem varies with the level of education and urban–rural setting. Furthermore the symptoms of mild anaemia can be vague but as anemia progresses more symptoms set in. Signs and symptoms include fatigue, low physical and mental capacity, headache, vertigo, leg cramps, pagophagia, cold intolerance, koilonychia, mucosal patches and angular stomatitis.

Classical laboratory investigations include haemoglobin level, serum iron concentration, serum transferrin and serum ferritin. However, due to limited resources we are not able to do all the above for our patients. Hence, it is recommended that we do at least serum ferritin levels at the 1\textsuperscript{st} antenatal visit along with a complete blood count. Management will depend upon whether we are using iron for treatment or prophylactic purposes. Prophylactic therapy is given to all pregnant patients in our setting.
Women should be counselled on how to take oral iron supplementation correctly. It should be on an empty stomach, 1 hour before meals, with a source of vitamin C to maximize absorption. Other medications or antacids, tea or coffee should not be taken at the same time.

**2\(^{nd}\) and 3\(^{rd}\) Trimester**

CBC should be repeated and parenteral iron should be given if haemoglobin is below 10.5 g/dL during 2\(^{nd}\) trimester and 11 g/dL in 3\(^{rd}\) trimester. There is no need to repeat the serum ferritin level if they were normal in 1\(^{st}\) trimester. Severe anaemia (< 7 g/dL) in unbooked patients presenting at or near term should be managed by giving a blood transfusion (This refers to those patients who seek help of their consulting physician for the first time and did not have any earlier antenatal care).
Recommendations for Iron deficiency anaemia

- Cut off value for Hb < 11 g/dl in 1st and 3rd trimester, 10.5 g/dl in 2nd trimester
- A prophylactic daily dose of 60 mg of elemental iron is recommended for non-anaemic pregnant mothers.\(^5^3\)
- High dose IV iron such as Iron sucrose or Ferric Carboxymaltose (FCM) should be given to pregnant mothers with Hb < 10.5 g/dL in the 2nd trimester and < 11 g/dl in 3rd trimester
- Where I/V iron is not available anaemic pregnant woman should betreated with daily iron (120 mg of elemental iron) and folic acid (400 μg or 0.4 mg) supplementation until her haemoglobin concentration rises to normal. She can then switch to the standard antenatal dose to prevent recurrence of anaemia.\(^5^3\)
- If Hb level is < 7g/dL in 2nd and 3rd trimester of pregnancy blood transfusion should be recommended after the evaluation of risks & benefits of blood transfusion.
- Folic acid should be commenced as early as possible (ideally before conception) to prevent neural tube defects

\(^*\) In settings where anaemia in pregnant women is a severe public health problem (40% or higher), a daily dose of 60 mg of elemental iron is preferred over a lower dose. Higher doses are recommended for Pakistan [51].\(^5^3\)

2. Post Natal Treatment

Postpartum iron deficiency anaemia is a major public health problem and is an important clinical entity as demonstrated by several studies that it is linked to postpartum anaemia, postpartum depression and fatigue, as well as other cognitive sequelae. It is associated with adverse future pregnancy outcomes for subsequent short inter pregnancies.\(^8^1\) All patients should have an active management of the third stage of labour to the baby’s minimize the blood loss at the time of delivery. If the baby’s APGAR score is good delayed cord clamping and waiting till the pulsations have stopped further helps the placental blood to reach the baby so that anaemia may be prevented.
Recommendations

- Immediate postpartum care (within 24 hours): If Hb level is < 10 g/dL patient should not be discharged from a hospital such patients should be given a single shot of high dose IV iron such as FCM/Iron Sucrose OR if patient’s Hb level is ≥ 10 g/dL after delivery, normal ferritin levels and haemodynamically stable, she should be discharged with advice of oral iron therapy at the discretion of health professional.

- Late postpartum care (after 24 hours): Patients who report back after delivery with Hb < 10 g/dL should also be given IV iron such as FCM and/or Iron Sucrose.

- Oral iron supplementation, either alone or in combination with folic acid (120 mg of elemental iron plus 400 µg folic acid), may be provided to postpartum women (haemodynamically stable) for 6–12 weeks following delivery for reducing the risk of anaemia in settings where gestational anaemia is of public health concern.

- All women with Hb < 7 g/dL should be considered for transfusion to achieve Hb > 7 g/dl.

- Contraceptive advice is mandatory to all patients.
Algorithm for the treatment of iron deficiency anaemia during 1st, 2nd, and 3rd trimester of pregnancy

Haemoglobin

1st Trimester

- Oral Iron Therapy
  - Various ferrous and ferric options are available. IPC offers a safe option.
  - Compliance Issues
  - Inadequate Response
  - Intolerance

Haemoglobin < 11 g/dL  1st and 3rd Trimester < 10.5 g/dL 2nd Trimester
Postpartum < 10 g/dL

2nd & 3rd Trimester

- Haemoglobin < 10.5 g/dL – 2nd trimester
- Haemoglobin < 11 g/dL – 3rd trimester

Iron Deficiency Anaemia

- Severe Anaemia
  - Blood Transfusion

Postpartum

< 10 g/dL

Haemoglobin < 7 g/dl

Intravenous Iron Therapy
Few I/V options available. FCM or Iron sucrose is safe and effective.
Algorithm for the treatment of iron deficiency anaemia during postpartum period

**Haemoglobin**

- **Haemoglobin <10g/dL**
  - Immediate postpartum care (within 24 hours)
    - Give single shot of high dose IV iron such as FCM/Iron Sucrose
  - Late postpartum care (after 24 hours)
    - Patients who report back after delivery with Hb < 10 g/dL should also be given IV iron such as FCM or Iron Sucrose.

- **Haemoglobin >10g/dL**
  - Immediate postpartum care (within 24 hours)
    - Discharge patient if ferritin levels normal and hemodynamically stable, with advice of oral iron therapy

- **Haemoglobin < 7 g/dl**
  - Severe Anaemia
    - Blood Transfusion

**Intravenous IV Therapy**

Oral iron supplementation, either alone or in combination with folic acid (120 mg of elemental iron plus 400 µg folic acid), should give to postpartum women (hemodynamically stable) for 6–12 weeks following delivery.
3. Available Drugs for Treatment of IDA in Pakistan

**Introduction**—Over the past years various oral, intramuscular and intravenous preparations of iron have been used for correction of IDA (Iron Deficiency Anaemia) in pregnant patients.\(^ {54} \) Oral iron is the preferred treatment option for most patients because of its considerable effectiveness, safety, and lower cost. However, the major problem with oral iron therapy, in its ferrous form, is poor tolerability and a high rate of adverse reactions of about 40% with the most common complaints being nausea, abdominal pain, diarrhoea and constipation.\(^ {55} \) The consequent drawbacks related to its side effects are poor compliance and limited absorption from the gut and hence low efficacy. (Gastrointestinal intolerance with oral iron therapy is dose related, whereas tolerance can be improved by ingesting the iron tablets along with food however this leads to a decrease in iron absorption). Furthermore, if functional iron deficiency develops in patients receiving erythropoietin who have a serum ferritin above 100 mg/L, then gastrointestinal absorption of iron will also be severely impaired.\(^ {56} \) Total iron replacement is possible with intravenous (IV) iron infusions with considerable safety and efficacy.\(^ {57} \)

**Oral versus IV iron** — The choice between oral and intravenous (IV) iron depends on a number of factors such as the severity of the anaemia, costs and availability of different iron replacement products, as well as patient tolerability. However, a large percentage of patients (especially those prescribed on ferrous sulphate report gastrointestinal side effects. Settings in which one route or the other may be preferable include the following.\(^ {58,59} \)

<table>
<thead>
<tr>
<th>Appropriateness</th>
<th>Oral</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oral supplements are the only form of iron available to many patients, especially those in resource-poor settings.(^ {58,59} )</td>
<td>IV iron is appropriate for patients who are unable to tolerate gastrointestinal side effects of oral iron and for those with severe/ongoing blood loss, Gastric surgery, Malabsorption syndromes.(^ {58,59} )</td>
</tr>
<tr>
<td>Target Audience</td>
<td>Oral supplements are generally used for infants, children, and adolescents.(^ {58,59} )</td>
<td>Older individuals, pregnant women and individuals with existing gastrointestinal disorders.(^ {58,59} )</td>
</tr>
<tr>
<td>Use of oral iron</td>
<td>Uses for oral iron supplements include the following: -Treatment of iron deficiency anaemia -Treatment of iron deficiency without anaemia -Nutritional support to prevent deficiency.(^ {58,59} )</td>
<td>Ongoing blood loss that exceeds replacement by oral iron intake (e.g., heavy uterine bleeding, mucosal telangiectasias). Conditions interfering with oral iron absorption. Co-existing inflammatory state that interferes with iron homeostasis.(^ {58,59} )</td>
</tr>
<tr>
<td>Advantage</td>
<td>Cost effective</td>
<td>Patients who cannot (or prefer not to) tolerate the gastrointestinal side effects of oral iron. Patients who prefer to replete iron stores faster than over the course of several months.(^ {60} )</td>
</tr>
<tr>
<td>Examples</td>
<td>Polysaccharide iron complex, Ferrous sulfate</td>
<td>ferric carboxymaltose (FCM), ferric gluconate (FG),</td>
</tr>
</tbody>
</table>
### I. ORAL IRON SALTS

<table>
<thead>
<tr>
<th>Side Effects</th>
<th>Preparations</th>
</tr>
</thead>
</table>
| Gastrointestinal side effects are extremely common with oral iron administration. These include metallic taste, nausea, flatulence, constipation, diarrhea, epigastric distress, and/or vomiting. | Ferrous fumarate – 324 or 325 mg tablet (contains 106 mg elemental iron per tablet)  
Ferrous gluconate  
Relatively inexpensive Over-The-Counter (OTC) preparations includes: heme iron polypeptide, carbonyl iron, ferric citrate, ferrous ascorbate, and ferrous succinate.  
ferumoxytol,  
iron sucrose (IS),  
iron isomaltoside (not available in the United States),  
Low molecular weight iron dextran (LMW ID). |

**I. ORAL IRON SALTS** such as ferrous fumarate, ferrous gluconate, and ferrous sulfate have been the mainstay of oral iron supplementation because they are inexpensive and effective at restoring iron balance with a favorable overall safety and tolerability profile. However, as discussed earlier, in some patients, absorption of oral iron salts is inadequate and poor tolerance results in reduced adherence to therapy. The newer polysaccharide iron complex and heme iron polypeptide products now offer alternative therapies with improved absorption and tolerability profile compared to the traditional iron salts.  

**A. Iron (III) hydroxide polymaltose complex (IPC)** is an iron preparation with non-ionic iron and polymaltose in a stable complex. Numerous clinical trials in men, women, children and infants have shown that IPC is effective in treating iron deficiency anaemia (IDA). IPC is best given with meals, and probably in a slightly higher iron dose than that of the classical salts. Its acceptance and compliance in patients shows an advantage over ferrous salts as reflected in several studies demonstrating a lower rate of treatment interruption related to a lower incidence of upper GIT adverse events.  

Meta-analysis of studies conducted in adult patients with iron deficiency anaemia, comparing IPC with ferrous sulfate in equivalent doses, suggested similar efficacy however, the tolerance of IPC in adults and its profile for adverse events was clearly better than that of ferrous sulfate.  

**B. Ferrous Gluconate** is used to prevent or treat low iron blood levels in iron deficiency anaemia. Studies have shown that Oral ferrous gluconate treatment for severe iron deficiency anaemia is well tolerated and highly effective in premenopausal women. The treated women did not exhibit any major side effect, only one serious side effect was reported (erythema nodosum). Mild self-limiting side effects including black discolouration of stools in 54% cases, nausea in 6%, constipation in 2% and diarrhoea in 2% were observed.
**C. Ferrous sulfate** is used to prevent or treat low iron blood levels in iron deficiency anaemia. It is the cheapest and most commonly prescribed oral iron supplement, showing a rapid rise in both serum iron concentration and Non-transferrin bound serum iron (NTBI) but the greatest frequency of adverse events at the same time. This may lead to poor compliance and hence poor results.

**D. Ferrous Fumarate** is used to prevent or treat low iron blood levels in iron deficiency anaemia. Ferrous fumarate, the least toxic iron (II) compound, causes fewer adverse events because of its low solubility and slow dissolution rate after oral administration. A 2013 systematic review included over 10,000 patients receiving different oral iron formulations. Gastrointestinal adverse effects were seen with all oral formulations (ferrous fumarate, 43 percent; ferrous gluconate, 31 percent; ferrous sulfate, 30 percent). Other supplements such as iron protein succinylate or ferrous glycine sulfate, which have enteric coatings (that reduces absorption) had lower frequencies of adverse effects.

**II. INTRAMUSCULAR (IM) IRON THERAPY**

Some preparations such as iron sorbitex, high molecular weight iron dextran, and low molecular weight iron dextran can be given intramuscularly (IM). However, as IM injections have some significant drawbacks they are generally not recommended. IM iron is painful and produces permanent skin staining. It is not safer than IV infusion. Its use is therefore discouraged.

**III. SPECIFIC IV IRON PREPARATIONS**

**A. Low Molecular Weight iron dextran (LMW-ID)** is the least expensive of the IV iron formulations that can be administered in a large dose (total dose infusion) and is seen as safe and effective in the settings of heavy uterine bleeding, pregnancy, postpartum, inflammatory bowel disease, gastric bypass, hereditary hemorrhagic telangiectasia, chronic kidney disease, and restless leg syndrome. A test dose is required prior to the first dose of LMW-ID. There are a limited number of studies available on the use of LMW-ID during pregnancy and the postpartum period. It is contraindicated during the 1st trimester. No serious adverse events have been associated with its use, but mild adverse events have been observed in 5% of cases.

**B. Iron sucrose (IS)** also called iron saccharate, is given over multiple infusions, with a maximum individual dose of 10 to 15 ml (equivalent to 200 to 300 mg elemental iron, based on a concentration of 20 mg elemental iron per ml). A test dose is recommended if the patient has a
history of drug allergies; otherwise, a test dose is not required. For patients with cancer receiving ESAs, 10 ml may be infused over 60 minutes every two to three weeks. Larger doses (i.e., doses above 300 mg) are not recommended. This product cannot be given intramuscularly. Numerous studies on its efficacy and safety, as compared with iron dextran and ferrous gluconate, reported that it was well tolerated; No hypersensitivity reactions or fatal events were observed except urticaria. Iron Sucrose are safe for use in: settings of dialysis, non-dialysis chronic kidney disease, inflammatory bowel disease, chemotherapy-induced anaemia, the peripartum period, gastric bypass, heavy uterine bleeding, and a host of other conditions associated with iron deficiency.

C. Ferric Carboxymaltose (FCM) is a colloidal iron hydroxide complex with tighter binding of elemental iron to the carbohydrate polymer than some other IV iron preparations and it can be given in large doses equivalent to 1000 mg of elemental iron. It may be given in short durations such as a 15-minute infusion. Its use has been approved in pregnant women from the 2nd trimester. Studies comparing IV versus oral iron therapies show that ferric carboxymaltose was associated with a higher rate of: patient tolerability, patient compliance, and target value achievement at lower doses with safety equal to but more effective than iron sucrose. Several trials establish the efficacy and safety of FCM in iron-deficient patients in many settings such as: heavy uterine bleeding, postpartum women, non-dialysis dependent chronic renal failure, inflammatory bowel disease, heart failure, chemotherapy associated anaemia without concomitant use of an erythropoietin stimulating agent (ESA), and patients non-responsive to oral iron. Numerous studies have also reported the safety profile use of FCM during pregnancy without serious adverse events. Initial experiences with FCM raised concerns about hypophosphatemia following administration but subsequently, only rare reports of clinical sequelae related to hypophosphatemia have been reported. Serum phosphate levels may need to be monitored in selected populations such as those with borderline phosphate levels at the baseline.

FCM offered an efficacious and time-efficient correction of IDA in women during the late stages of pregnancy along with improvements in QoL and significant decrease in gastrointestinal side effects. In patients who are intolerant and need a quick correction of iron deficit prior to delivery (and identification or non-correction of IDA), FCM is an option for anaemia correction with a safety profile similar to oral iron. Efficacy and Safety of ferric carboxymaltose and other formulations in iron deficient patients have been widely studied in randomized controlled trials,
showing significant improvements in serum ferritin (µg/L) with ferric carboxymaltose compared to oral iron (delta 172.8; 95 % CI 66.7–234.4) and in haemoglobin (g/dL) levels with respect to ferric gluconate (delta 0.6; 95 % CI 0.2–0.9), oral iron (delta 0.8; 95 % CI 0.6–0.9) and placebo (delta 2.1; 95 % CI 1.2–3.0). The conclusion was that all currently available intravenous iron preparations appear to be safe and effective, but ferric carboxymaltose seems to provide a better and quicker correction of haemoglobin and serum ferritin levels in iron deficient patients.\textsuperscript{32}

D. Iron isomaltoside has a matrix structure that results in tight iron binding and slow release of labile free iron, allowing administration in a single infusion, at a dose of 20 mg/kg, over 15 minutes without a test dose. A 2017 trial comparing a single infusion of iron isomaltoside (500 or 1000 mg, depending on body weight and haemoglobin level) or multiple infusions of iron sucrose (given as 200 mg infusions, for a total dose based on body weight and haemoglobin), showed that a greater number of patients in the iron isomaltoside group had an increase in haemoglobin of ≥ 2 g/dL (69 versus 52 percent; p <0.0001). Rates of serious adverse events did not differ (0.6 percent in both groups).\textsuperscript{76}

E. Iron Sorbitol is a complex of ferric, sorbitol and citric acid, stabilized with dextrin and sorbitol. Its use is only in the treatment of proven iron deficiency anaemia, where oral therapy is ineffective or inappropriate through parenteral route. Severe anaphylactic reactions may occur after parenteral administration. As evident from the study, the practice of prescribing iron sorbitol in a dose of 10 ampoules (75 mg/ampoule) with continuing oral iron therapy throughout pregnancy does not fulfill the goal of iron therapy. It is impractical to check the compliance in these patients, and the therapy is cumbersome and prolonged.\textsuperscript{77}

IV. OTHER IV IRON PREPARATIONS NOT AVAILABLE IN PAKISTAN

A. Ferric Gluconate also called ferric gluconate complex, can be given over multiple infusions. A test dose is recommended if the patient has a history of drug allergies.\textsuperscript{69} There few studies on its use during pregnancy and there are data concerning its use during the neonatal period. It is contraindicated during the 1\textsuperscript{st} trimester. No serious adverse events have been linked with its use.\textsuperscript{41,69}

B. Ferumoxytol is composed of super paramagnetic iron oxide nanoparticles coated with a LMW semi synthetic carbohydrate.\textsuperscript{60,78} In a 2018 trial of ferumoxytol (two infusions of 510 mg
for a total of 1020 mg) versus ferric carboxymaltose (two infusions of 750 mg for a total of 1500 mg), showed both groups to have comparable increases in haemoglobin (approximate increase, 1.5 g/dL) with no clinical sequelae related to hypophosphatemia in either group. Ferumoxytol can cause a brighter signal on magnetic resonance imaging (MRI) scans, therefore if an MRI is planned within three months of administration, the radiologist should be notified accordingly. There are no published data on the safety and efficacy of ferumoxytol in pregnancy.

C. Iron Polymaltose there is a limited number of studies on the use of iron polymaltose during pregnancy and the neonatal period, but no serious adverse events have been reported. Its administration is limited to the IM route.

Prevention of Anaemia in Pregnancy

1. **Health and nutrition education of women**
   - Women should be educated to improve over all dietary intake and consumption of iron and folate rich food stuffs. In addition, knowledge and practice enhancement through counselling and behaviour change communication are vital aspects of improving diet.
   - Women should be encouraged to take diet which includes meat, poultry, fish, beans, nuts, seeds, leafy greens, eggs, fruits like banana and melons. They should be educated about supplement high in a vitamin C like tomato juice or oranges; this will help absorption of iron.

2. **Optimal birth spacing**
   - Women should be counselled to have birth spacing to prevent maternal anaemia and low birth weight babies.

3. **Fortification of food**
   - It can be a cost effective way to improve iron status and is available for wheat, maize, flour and rice.

4. **Haemoglobin estimation**
   - Haemoglobin estimation in adolescent school girls and women intending to become pregnant for detection and treatment of anaemia prior to pregnancy

5. **Iron Folic acid (IFA)supplementation**
   - Women in the postpartum period should have iron and folic acid supplementation so that she can replenish iron stores to prevent anaemia.
     - WHO recommendations - 2016
o Daily oral iron and folic acid supplementation with 30 mg to 60 mg of elemental iron* and 400 µg (0.4 mg) folic acid** is recommended for pregnant women to prevent maternal anaemia, puerperal sepsis, low birth weight, and preterm birth.***
  - *The equivalent of 60 mg of elemental iron is 300 mg ferrous sulfate heptahydrate, 180 mg ferrous fumarate or 500 mg of ferrous gluconate.
  - ** Folic acid should be commenced as early as possible (ideally before conception) to prevent neural tube defects.
  - *** This recommendation supersedes the previous recommendation found within the WHO guideline ‘Daily iron and folic acid supplementation in pregnant women’ (2012).

6. **Prevention of other nutritional deficiencies**
   - Other nutritional supplements should be given such as vitamin B12 and vitamin A.

7. **Promoting safe water, sanitation and hygiene (WASH)**
   - WASH has a great impact on the general nutrition status and would also indirectly affect the anaemia status of the women.

8. **Control of helminthic infestation**
   - Periodic treatment (deworming medication such as albendazole and mebendazole as a routine part where hookworm prevalence is >20%) with improvement of water and sanitation and health education can reduce the transmission of soil-transmitted helminths and schistosomiasis infections.

9. Prevention and treatment of infections such as malaria and tuberculosis are vital for the prevention of anaemia.

10. **Treatment of conditions causing blood loss**
    - This includes conditions of blood loss such as haemorrhoids, menorrhagia due to fibroid or dysfunctional uterine bleeding and requires prompt medically or surgically.

11. **Community-based distribution** (home visits) of iron and other micronutrient supplements to the most vulnerable groups, particularly where health services are not well utilized, and other high-risk group.80

12. **Promote use of ITB (bed nets).**80

13. **Reproductive health**
    Promote the care of women (raising awareness about danger signs during pregnancy and postpartum periods and what to do about them; the need for antenatal and postpartum care and adequate diet for women).80
14. Private sector (food and pharmaceutical manufacturers, marketers, distributors)
Promote production and sale of iron and micronutrient supplements, fortified foods, ITB (Bed nets) and family planning by private vendors, marketers, distributors.  

Conclusion
The role of I/V iron as a safe and effective option for quick correction of iron deficiency and iron deficiency anaemia along with its protective role in the postpartum period needs to be underscored as part of Pakistan guidelines for management of iron deficiency and iron deficiency anaemia. This can also serve for guidance of various societies as well as physicians in improving health outcomes in pregnant women.

REFERENCES


31. World Health Organization. Assessing the iron status of population: report of a joint world health organization / centre for disease control and prevention technical consultation on the assessment of iron status at the population level. 2007. Available from:


43. Sharran Grey, Helen Wright, Muhammad Athar. Management of anaemia in primary care pathway NHS foundation trust. Bolton NHS version1 ate Nov; 2015.Aaavilable from:

45. Baker RD, Greer FR. Diagnosis and prevention of iron deficiency and iron-deficiency anaemia in infants and young children (0-3 years of age). Pediatrics. 2010;126(5):1040-50


47. National Institute of Population Studies (NIPS) [Pakistan] and ICF. 2018. Pakistan Demographic and Health Survey 2017-18. Islamabad, Pakistan, and Rockville, Maryland, USA: NIPS and ICF.


